ArticleHistology and histopathology2026
Protective effects of
Article in Histology and histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundExcessive exposure to blue light (BL) from light-emitting diodes (LEDs) induces oxidative stress and photoreceptor degeneration, contributing to retinal damage.
methodsWe investigated the protective effects of AME
resultsAME pretreatment preserved the structural integrity of the photoreceptor layer, maintained outer segment and synaptic ribbon architecture, and reduced 8-hydroxy-2'-deoxyguanosine (8-OHdG) accumulation in BL-exposed retinas. In 661W cells, AME enhanced cell viability, decreased apoptosis, and attenuated ROS production. Furthermore, AME upregulated Nrf2 expression and promoted its nuclear translocation, suggesting activation of the antioxidant response pathway.
conclusionsAME exerts protective effects against BL-induced retinal degeneration and oxidative stress-induced photoreceptor apoptosis, potentially through activation of the Nrf2 pathway. These findings highlight the therapeutic potential of AME in preventing or mitigating retinal damage associated with oxidative stress.
Indexed as
Identifiers
41742865What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.